Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the ...

Bright Minds Biosciences (DRUG) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi.Invest with Confidence: ...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence ...

The average Revenue of companies in the Sector is 663.5 M with a standard deviation of 2.237 B. Bright Minds Biosciences Inc's Revenue of - ranks in the - percentile for the Sector. The following ...

Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ...